3Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women.Maturitus, 1996, 23(3): 259-263.
4Cardozo L, Bachmann G, McClish D, et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: Second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol, 1998,92(4 pt 2): 722-727.
5Alexander N J, Baker E, Kaptein M, et al. Why consider vaginal drug administration? Fertil Steril, 2004, 82(1): 1-12.
6Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev, 2003, 4:CD001500.
7Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. Urology, 2003, 62[Suppl 4A]: 45-51.
8Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women. Cochrane Database Syst Rev, 2003, 2:CD001405.
9Lose G, Englev E. Oestrodiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. Br J Obstet Gynaecol, 2000, 107(8):1029-1034.
10Grady D, Brown JS, Vittinghoff E, et al. Postmenopausal hormones and incontinense:the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol, 2001, 97(1): 116-120.
4[2]Sorahan T,Lancashire,Stewart A,et al.Prehnancy ultrasound and childhood cancer.A second from the lxford survey of childhood cancers[J].Br J Obstet and Gynaecol,1995,102:8.
5[8]Gregor Reid.Probiotie agents to protect the urogenital tract against jnfection[J].Clin Nutri,2001,73(1):437-443.
